Trends in the Development of Met Inhibitors for Hepatocellular Carcinoma
Authors:
Open Access
- 17 March 2016
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 12 (10) , 1275-1286
Abstract
Hepatocellular carcinoma is the third most common cause of cancer-related deaths worldwide. The multikinase inhibitor sorafenib has improved survival and is now considered the standard of care; however, the benefits are still disappointing, and thus, new effective treatments are required. In human hepatocellular carcinoma, MET, which is encoded by the HGFR gene, is activated by amplification, overexpression or mutation, and it has recently emerged as a possible therapeutic target in various tumors including hepatocellular carcinoma. In fact, some drugs targeting the HGF/MET axis are currently under investigation in clinical trials. Here, we review the role of MET and trends in the development of MET inhibitors for hepatocellular carcinoma.Keywords
This publication has 66 references indexed in Scilit:
- Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In VitroClinical Cancer Research, 2012
- Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET KnockdownMolecular Cancer Therapeutics, 2012
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating CellsPLOS ONE, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 2007
- Association between serum hepatocyte growth factor and survival in untreated hepatocellular carcinomaJournal of Gastroenterology, 2004
- A Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive GrowthCell, 2001
- Expression of hepatocyte growth factor and its receptor c- met proto-oncogene in hepatocellular carcinomaHepatology, 1997
- Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinomaJournal of Hepatology, 1996